GSK and Avalon Ventures are having success with the Biotechs created under their collaboration. Sitari Pharmaceuticals and Silarus Therapeutics have achieved their first milestones, and there’s a 8th Biotech in the making.
This incubator is COI Pharmaceuticals, a ‘venture-pharma entity’ that provides R&D infrastructures and industry mentors to create new Biotechs.
Now, the collaboration is reaping some successes. The first two Biotechs created by the programme have reached their first milestones – establishing a plan to identify a clinical candidate.
The first is Sitari Pharmaceuticals, which is developing treatments for celiac disease. Its therapeutic approach targets Transglutaminase 2 (TG2), an enzyme that is thought to play an important role in this autoimmune disease.
The other is Silarus Therapeutics, which targets erythroferrone.